Clinical Trial Update: Innovation-TiFP4-C101: A Study to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629 [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study comparing controlled-release formulations of TMC114 (darunavir) and TMC41629 to an immediate-release formulation; the trial has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TMC114 (darunavir) (darunavir)
• TMC41629

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV-I | Phase 1 | Status: COMPLETED